Insider Selling: Cryoport, Inc. (NASDAQ:CYRX) CFO Sells 1,659 Shares of Stock

Cryoport, Inc. (NASDAQ:CYRX - Get Free Report) CFO Robert Stefanovich sold 1,659 shares of the business's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $6.29, for a total value of $10,435.11. Following the sale, the chief financial officer now owns 191,419 shares of the company's stock, valued at $1,204,025.51. The trade was a 0.86 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Robert Stefanovich also recently made the following trade(s):

• On Monday, March 10th, Robert Stefanovich sold 1,256 shares of Cryoport stock. The shares were sold at an average price of $4.88, for a total transaction of $6,129.28.

Cryoport Trading Down 1.4 %

NASDAQ:CYRX traded down $0.08 on Friday, hitting $5.69. The stock had a trading volume of 397,451 shares, compared to its average volume of 528,421. The company has a fifty day moving average price of $6.81 and a two-hundred day moving average price of $7.38. Cryoport, Inc. has a 1-year low of $4.58 and a 1-year high of $20.11. The company has a quick ratio of 5.32, a current ratio of 5.70 and a debt-to-equity ratio of 0.48. The stock has a market cap of $283.99 million, a price-to-earnings ratio of -1.68 and a beta of 1.67.

Cryoport (NASDAQ:CYRX - Get Free Report) last released its quarterly earnings data on Tuesday, March 4th. The company reported ($0.42) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.09). The business had revenue of $59.53 million during the quarter, compared to analyst estimates of $58.71 million. Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. During the same quarter in the prior year, the company posted ($0.29) earnings per share. Equities research analysts expect that Cryoport, Inc. will post -0.99 earnings per share for the current fiscal year.

Remove Ads

Hedge Funds Weigh In On Cryoport

Hedge funds have recently modified their holdings of the business. Point72 Asia Singapore Pte. Ltd. raised its holdings in Cryoport by 148.7% in the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company's stock valued at $28,000 after buying an additional 2,120 shares during the period. Lazard Asset Management LLC purchased a new position in shares of Cryoport during the fourth quarter worth $51,000. Avanza Fonder AB acquired a new stake in shares of Cryoport in the fourth quarter valued at $64,000. Quarry LP purchased a new stake in shares of Cryoport in the 4th quarter valued at $69,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in Cryoport during the 3rd quarter worth about $82,000. 92.90% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts recently issued reports on CYRX shares. Needham & Company LLC reaffirmed a "buy" rating and set a $11.00 price objective on shares of Cryoport in a research note on Wednesday, March 5th. Guggenheim assumed coverage on Cryoport in a research report on Thursday, December 19th. They issued a "buy" rating and a $11.00 price target for the company. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $11.50.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.